Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer

키워드

참고문헌 (34)

1. Cheang MC, "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer", J Natl Cancer Inst, 101, pp.736~750 (2009)
2. Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
3. Goldhirsch A, "Strategies for subtypes:dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
4. Neubauer H, "Changes in tumour biological markers during primary systemic chemotherapy(PST)", Anticancer Res, 28, pp.1797~1804 (2008)
5. Untch M, "Current and future role of neoadjuvant therapy for breast cancer", Breast, 23, pp.526~537 (2014)
6. Teshome M, "Neoadjuvant therapy in the treatment of breast cancer", Surg Oncol Clin N Am, 23, pp.505~523 (2014)
7. Loibl S, "Neoadjuvant treatment of breast cancer : clinical and research perspective", Breast, 24(Suppl 2), pp.S73~S77 (2015)
8. Ge WK, "Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients", Thorac Cancer, 6, pp.64~69 (2015)
9. Piper GL, "Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status", Am Surg, 70, pp.1103~1106 (2004)
10. Meattini I, "Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management : single-institution experience and review of published literature", Eur J Surg Oncol, 43, pp.642~648 (2017)
11. Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
12. Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists Clinical Practice Guideline Focused Update, 2018, pp.36, 2105~2122
13. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
14. Cho U, "The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value", Appl Immunohistochem Mol Morphol, 24, pp.159~166 (2016)
15. Dowsett M, "Assessment of Ki67 in breast cancer : recommendations from the International Ki67 in Breast Cancer working group", J Natl Cancer Inst, 103, pp.1656~1664 (2011)
16. Zidan A, "Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma", J Clin Pathol, 50, pp.27~29 (1997)
17. Rakha EA, "An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens", J Clin Pathol, 60, pp.1300~1306 (2007)
18. Park SY, "The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer", Am J Surg, 197, pp.266~269 (2009)
19. Ricci MD, "Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer", Rev Assoc Med Bras (1992), 58, pp.532~536 (2012)
20. Ozdemir A, "Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma", Clin Breast Cancer, 7, pp.791~795 (2007)
21. Ough M, "A comparative analysis of core needle biopsy and final excision for breast cancer : histology and marker expression", Am J Surg, 201, pp.692~694 (2011)
22. Chen J, "Comparison of core needle biopsy and excision specimens for the accurate evaluation of breast cancer molecular markers : a report of 1003 cases", Pathol Oncol Res, 23, pp.769~775 (2017)
23. 유기호, "Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry", Journal of Breast Cancer, 20(3), pp.297~303 (2017), 한국유방암학회[DOI]
24. Ensani F, "The core needle and surgical biopsy concordance to detect estrogen, progesterone, and Her-2 receptors in breast cancer : a comparative study", Iran J Pathol, 12, pp.202~208 (2017)
25. Liu M, "Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication", J Clin Pathol, 71, pp.1084~1089 (2018)
26. Lorgis V, "Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour", Breast, 20, pp.284~287 (2011)
27. Chen X, "Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer", BMC Cancer, 13, pp.390~ (2013)
28. Usami S, "Reliability of prognostic factors in breast carcinoma determined by core needle biopsy", Jpn J Clin Oncol, 37, pp.250~255 (2007)
29. Robertson S, "Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant", Breast Cancer Res Treat, 174, pp.795~805 (2019)
30. Mazari FA, "Human epidermal growth factor 2-positive breast cancer with mammographic microcalcification : relationship to pathologic complete response after neoadjuvant chemotherapy", Radiology, 288, pp.366~374 (2018)
31. Zhong Nie, "Microcalcification-associated breast cancer: HER2-enriched molecular subtype is associated with mammographic features", The British Journal of Radiology, pp.20170942~ (2018), British Institute of Radiology[DOI]
32. Fishman JE, "US-guided core-needle biopsy of the breast: how many specimens are necessary?", Radiology, 226, pp.779~782 (2003)
33. McIlhenny C, "Optimum number of core biopsies for accurate assessment of histological grade in breast cancer", Br J Surg, 89, pp.84~85 (2002)
34. Greer LT, "Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?", J Am Coll Surg, 216, pp.239~251 (2013)

관련 논문AI추천